Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics and medical technologies addressing central nervous system (CNS) disorders, oncology, and ophthalmology. The company primarily operates within the biotechnology and pharmaceutical development industries, with an emphasis on late preclinical to clinical-stage assets intended for licensing, co-development, or commercialization through partners rather than large-scale in‑house sales.
The company’s primary value drivers are its drug candidates for major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), and oncology-related indications, as well as selected medical device technologies. ABVC positions itself as a platform-oriented developer, seeking to advance assets through defined clinical milestones before monetization. The company was founded in 2013 and later became publicly listed on NASDAQ under the ticker ABVC, evolving from a regional biotech developer into a U.S.-listed entity with cross-border research and investment activities. Certain aspects of early corporate formation and founding leadership show minor inconsistencies across public disclosures; data is generally consistent but some historical details remain inconclusive based on available public sources.
Business Operations
ABVC BioPharma conducts operations primarily through its biopharmaceutical development segment, which encompasses drug discovery, clinical trial management, regulatory preparation, and intellectual property development. Revenue generation to date has been limited and non-recurring, historically derived from licensing arrangements, milestone payments, and strategic transactions, rather than product sales, reflecting its clinical-stage profile.
The company operates through a network of wholly owned and majority-controlled subsidiaries, including ABVC BioPharma USA, Inc., BioFirst Corporation, and other development-focused entities used to hold specific technology assets or regional operations. ABVC does not currently maintain large-scale manufacturing infrastructure and instead relies on contract research organizations (CROs) and third-party clinical partners. Public disclosures confirm U.S.-based regulatory oversight and trial activity, while certain subsidiary functions in Asia are reported but specific operational scopes vary across filings and are partially inconclusive.
Strategic Position & Investments
ABVC’s strategy centers on asset-focused clinical advancement, prioritizing programs that address large unmet medical needs and have potential for out-licensing or co-development with established pharmaceutical companies. Growth initiatives emphasize advancing CNS candidates through Phase II clinical trials, which the company identifies as a key inflection point for valuation and partnership discussions.
The company has pursued targeted investments and internal spin-out structures to isolate risk and attract strategic capital, with several subsidiaries holding distinct technology platforms or regional rights. ABVC has disclosed interests in emerging CNS therapeutics, precision oncology approaches, and ophthalmic diagnostic technologies, though the commercial readiness of several assets remains under development. Where acquisition or investment timelines differ across public disclosures, data is inconclusive based on available public sources.
Geographic Footprint
ABVC BioPharma is headquartered in the United States, with its principal executive offices located in California. The company maintains an operational and investment presence across North America and Asia, reflecting its dual focus on U.S. capital markets and international research collaboration.
Clinical development activities are primarily aligned with U.S. regulatory standards, while certain research, licensing, and subsidiary operations extend into Taiwan and other parts of Asia. ABVC does not report broad commercial distribution operations; instead, its geographic influence is driven by cross-border R&D coordination, intellectual property ownership, and strategic investment structures rather than physical product sales networks.
Leadership & Governance
ABVC BioPharma is led by an executive team with backgrounds in clinical medicine, pharmaceutical development, and corporate finance, reflecting the company’s emphasis on regulatory execution and strategic transactions. Leadership communications emphasize capital efficiency, milestone-driven development, and partnership-oriented growth as core governance principles.
Key executives include:
- Uttam Patil, MD – President and Chief Executive Officer
- Sam Yang – Chairman of the Board
- Ying-Jen Chen – Chief Financial Officer
- Sherry Lin – Director
While executive titles and board composition are consistently reported in SEC filings, certain biographical details and historical role transitions show minor variation across public disclosures; however, no material conflicts have been identified.